BiotechTube

Radspherin

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peritoneal Carcinomatosis

Conditions

Peritoneal Carcinomatosis, Ovarian Cancer

Trial Timeline

Jun 8, 2020 → Aug 1, 2025

NCT ID
NCT03732768

About Radspherin

Radspherin is a phase 1 stage product being developed by Oncoinvent for Peritoneal Carcinomatosis. The current trial status is active. This product is registered under clinical trial identifier NCT03732768. Target conditions include Peritoneal Carcinomatosis, Ovarian Cancer.

What happened to similar drugs?

3 of 7 similar drugs in Peritoneal Carcinomatosis were approved

Approved (3) Terminated (1) Active (4)
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
✅ertapenemMerckApproved
🔄PA21Kissei PharmaceuticalPhase 3
🔄Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3
✅Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
✅Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06504147Phase 2Recruiting
NCT03732768Phase 1Active
NCT03732781Phase 1/2Completed

Competing Products

20 competing products in Peritoneal Carcinomatosis

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
MCY-M11 + CyclophosphamideMaxCytePhase 1
11
R744 + R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
AbemaciclibEli LillyPhase 1
36
M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)AbbViePhase 1/2
32
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLDAstraZenecaPhase 2
35
Tremelimumab + OlaparibAstraZenecaPhase 1
21
ertapenemMerckApproved
43
Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + PlaceboNovartisPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2PfizerPhase 1/2
24
Bevacizumab + Nivolumab + RucaparibBristol Myers SquibbPhase 2
39
IniparibSanofiPhase 2
35
Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3
40
nanoliposomal irinotecanIpsenPhase 1
26
Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
32
Anti-Adhesion ProductBaxterPhase 2
32
PioglitazoneBaxterPre-clinical
23
Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved
47